Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019

Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in s...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-02, Vol.18 (2), p.e0281555-e0281555
Main Authors: Nduaguba, Sabina O, Tran, Phuong T, Choi, Yoonyoung, Winterstein, Almut G
Format: Article
Language:English
Subjects:
Age
Ambulatory care
Antibodies, Monoclonal, Humanized - therapeutic use
Antiviral Agents - therapeutic use
Biology and life sciences
Bronchitis
Child
Child, Preschool
Children
Codes
Confidence intervals
Health risks
Hospitalization
Humans
Immunoprophylaxis
Infant
Infants
Infections
Medicine and Health Sciences
Palivizumab - therapeutic use
Pediatrics
People and Places
Pneumonia
Population statistics
Reinfection
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus, Human
Risk
Risk groups
Seasons
United States - epidemiology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although respiratory syncytial virus (RSV) immunoprophylaxis is recommended for high-risk infants, the American Academy of Pediatrics (AAP) recommends against immunoprophylaxis in the same season following a breakthrough hospitalization due to limited risk for a second hospitalization. Evidence in support of this recommendation is limited. We estimated population-based re-infection rates from 2011-2019 in children
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0281555